Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | TSHR | P16473 | 3/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 2/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1714603 | 0.98 | ALDH1A1 (0.35) | ALDH1A1TSHRSMN1; SMN2THRBEPHX2 | |
| SCHEMBL1714426 | 0.91 | EPHX2 (0.37) | ALDH1A1TSHRSMN1; SMN2THRBEPHX2 | |
| SCHEMBL1714936 | 0.91 | EPHX2 (0.37) | ALDH1A1TSHRSMN1; SMN2THRBEPHX2 | |
| SCHEMBL5255816 | 0.81 | — | — | |
| SCHEMBL1715215 | 0.80 | ALDH1A1 (0.42) | ALDH1A1TSHRKMT2AHPGD | |
| SCHEMBL1714898 | 0.80 | ALDH1A1 (0.39) | ALDH1A1TSHRTHRB | |
| SCHEMBL4912343 | 0.79 | — | — | |
| SCHEMBL25996476 | 0.79 | ALDH1A1 (0.44) | ALDH1A1TSHRSMN1; SMN2THRBEPHX2 | |
| SCHEMBL1714074 | 0.78 | TSHR (0.41) | ALDH1A1TSHRKMT2AHPGD | |
| SCHEMBL1715062 | 0.78 | ALDH1A1 (0.38) | ALDH1A1TSHRTHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107001654-B | Method for curing curable composition | 巴斯夫欧洲公司 | 2020-11-20 | — | — | CN | disclosed |
| US-10577471-B2 | Method for curing curable compositions | BASF SE (DE) | 2020-03-03 | — | — | US | disclosed |
| EP-3201261-B1 | METHOD FOR CURING CURABLE COMPOSITIONS | BASF SE (DE) | 2018-12-12 | — | — | EP | disclosed |
| US-20180148554-A9 | METHOD FOR CURING CURABLE COMPOSITIONS | BASF SE (DE) | 2018-05-31 | — | — | US | disclosed |
| US-9840635-B2 | Binding agent systems | CONSTRUCTION RESEARCH & TECHNOLOGY, GMBH (DE) | 2017-12-12 | — | — | US | disclosed |
| US-20170306118-A1 | METHOD FOR CURING CURABLE COMPOSITIONS | BASF SE (DE) | 2017-10-26 | — | — | US | disclosed |
| EP-3201261-A1 | METHOD FOR CURING CURABLE COMPOSITIONS | BASF SE (DE) | 2017-08-09 | — | — | EP | disclosed |
| EP-3066161-B1 | COATINGS FOR USE AS ADHESIVE | CONSTRUCTION RESEARCH & TECHNOLOGY GMBH (DE) | 2017-07-05 | — | — | EP | disclosed |
| US-20160280954-A1 | NOVEL BINDING AGENT SYSTEMS | SIKA TECHNOLOGY AG (CH) | 2016-09-29 | — | — | US | disclosed |
| EP-3066161-A1 | NOVEL BINDING AGENT SYSTEMS | Construction Research & Technology GmbH (DE) | 2016-09-14 | — | — | EP | disclosed |
| US-20070135556-A1 | Coating materials containing alpha-(1'-hydroxyalkyl)acrylates | BASF AKTIENGESELLSCHAFT (DE) | 2007-06-14 | — | — | US | disclosed |
| EP-1695146-A1 | COATING MATERIALS CONTAINING alpha-(1 -HYDROXYALKYL)ACRYLATES | BASF AKTIENGESELLSCHAFT (DE) | 2006-08-30 | — | — | EP | disclosed |
| EP-1546163-B1 | METHOD FOR THE PRODUCTION OF ACYLPHOSPHINE OXIDES | BASF AG (DE) | 2006-07-12 | — | — | EP | disclosed |
| US-20060052636-A1 | Method for the production of acylphosphine oxides | BASF AKTIENGESELLSCHAFT (DE) | 2006-03-09 | — | — | US | disclosed |
| EP-1613638-A2 | METHOD FOR PRODUCING ACYLPHOSPHINE OXIDE SOLIDS | BASF AKTIENGESELLSCHAFT (DE) | 2006-01-11 | — | — | EP | disclosed |
| US-20050222294-A1 | Acyl- and bisacylphosphine derivatives | IGM GROUP B.V. (NL) | 2005-10-06 | — | — | US | disclosed |
| WO-2005057286-A1 | COATING MATERIALS CONTAINING α-(1'-HYDROXYALKYL)ACRYLATES | BASF AKTIENGESELLSCHAFT (DE) | 2005-06-23 | — | — | WO | disclosed |
| WO-2004094439-A2 | METHOD FOR THE PRODUCTION OF ACYLPHOSPHINES | BASF AKTIENGESELLSCHAFT (DE) | 2004-11-04 | — | — | WO | disclosed |
| WO-2004087723-A2 | METHOD FOR PRODUCING ACYLPHOSPHINE OXIDE SOLIDS | BASF AKTIENGESELLSCHAFT (DE) | 2004-10-14 | — | — | WO | disclosed |
| US-20040116702-A1 | Alkoxylated acyl-and bisacylphoshine derivatives | BASF AKTIENGESELLSCHAFT (DE) | 2004-06-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060052636-A1 | Method for the production of acylphosphine oxides | AGPAT5, PNPO, PHOSPHO1 | ALDH1A1 2749/4885TSHR 3990/4885SMN1; SMN2 3794/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.